The murine double minute (MDM) oncogene family, consisting of MDM2 and MDMX, has been demonstrated to be a promising molecular target for the prevention and treatment of various types of human cancer, including prostate cancer (Burgess et al., 2016; Karni-Schmidt et al., 2016; Lemos et al., 2016). Here, MDM2 is linked to prostate carcinoma.